Neue Zulassung für Osimertinib zur adjuvanten Therapie

Nach überzeugenden Resultaten der Phase-III-Studie ADAURA wurde die Indikation für Osimertinib in der Schweiz erweitert. So darf das Medikament nun auch zur adjuvanten Therapie beim nicht-kleinzelligen Lungenkarzinom (NSCLC) mit EGRF-Mutation im Frühstadium eingesetzt werden.

Damit Sie den vollständigen Artikel lesen können, müssen Sie sich einloggen oder neu registrieren.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

immer aktiv

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Dauer	Beschreibung
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Markt & Medizin, Onkologie, Pneumologie, Studien

Neue Zulassung für Osimertinib zur adjuvanten Therapie

LOGIN

Registrieren

Hobit macht Immunzellen zu Killern

miRNA-506-Quaking-Achse reguliert assoziierte Gennetzwerke

Patienten mit chronischer Lungenerkrankung optimal behandeln

FcεRI als potenzieller Biomarker für das Therapieansprechen auf Omalizumab

Legal